Is Semax the same as semaglutide? No — and the fact that people ask is entirely down to the names. GLP-1 S is a 31-residue modified incretin analogue. Semax is a seven-residue fragment of a pituitary hormone with a protective tail. They share four letters and nothing else.
Proxiva Literature ReviewWhat the published research does and does not support
Key takeaways
- Different molecules entirely. 31 residues with a fatty-acid modification versus 7 residues with a proline tail.
- GLP-1 S derives from glucagon-like peptide-1. Semax derives from ACTH(4-10). Unrelated parent hormones.
- Semax contains methionine and oxidises on air contact — a specific, predictable handling liability.
- GLP-1 S carries modifications, so its theoretical mass cannot be derived from the amino-acid sequence.
- The name similarity is coincidence: 'Sema' in one abbreviates the compound, in the other it is part of a coined research name.
Why the confusion exists at all
You have seen two words that begin with the same three letters, and you want to know whether they are the same substance. Are they?
No. And the reason is worth understanding, because it protects you from making the same mistake again with a different pair.
Ask yourself where you encountered each one. Did you meet the first in a discussion of weight and metabolic health? And the second somewhere else entirely — attention, stress, cognition? That mismatch is your first clue, and it is a reliable one.
So why do the names resemble each other? Coincidence, and a narrow one at that. They share three opening letters. They share nothing after them, and nothing before them either in the sense that matters: they were coined in different countries, in different decades, under different naming conventions, by people who had no knowledge of each other's work.
Does that seem like a thin basis for confusion? It is. But consider how you actually encounter these names — in passing, half-read, in a list, on a forum. You are not comparing them letter by letter. You are pattern-matching, and three shared letters at the front of a word is exactly what pattern-matching latches onto.
What should you take from this? That the resemblance is doing no work. It is not a hint of hidden kinship. It is an accident of spelling, and the sections below show you how the naming system itself proves that.
What each molecule is
| GLP-1 S | Semax | |
|---|---|---|
| Length | 31 residues + modifications | 7 residues |
| Parent | Glucagon-like peptide-1 | ACTH (residues 4–10) |
| Key modification | Fatty acid via a linker | Pro-Gly-Pro tail |
| Purpose of that modification | Albumin binding, slows clearance | Resists peptidase cleavage |
| Research context | Incretin receptor signalling | Neurotrophic, cognitive |
| Specific liability | Long chain — many hydrolysis sites | Methionine oxidation |
| Mass derivable from sequence? | No — modifications add mass | Yes |
GLP-1 S
A 31-amino-acid backbone based on the native GLP-1 sequence, with a substitution that blocks enzymatic cleavage and a fatty acid attached to a lysine side chain via a short spacer. That fatty acid binds reversibly to serum albumin, which slows clearance dramatically — native GLP-1 has a half-life measured in minutes.
Semax
Seven residues: the ACTH(4-10) fragment — methionine, glutamate, histidine, phenylalanine — with proline-glycine-proline appended. Proline's ring structure makes adjacent peptide bonds poorly cleaved by peptidases, so the tail is what lets a short fragment survive long enough to be studied at all.
One design problem, two solutions
The only genuine thing these compounds share is the problem their modifications solve.
Native peptide fragments and native hormones are both cleared fast — by peptidases attacking chain ends, or by renal filtration, or both. A molecule that survives minutes cannot be studied properly.
Semax blocks the attack. Proline at both ends of the appended tail makes those bonds poor substrates for the enzymes that would otherwise trim the fragment.
GLP-1 S hides. The fatty acid grips albumin — the most abundant plasma protein, which circulates for weeks — so the bound molecule is shielded from clearance while a small free fraction stays available.
The same problem recurs across a catalogue with different answers: Tesamorelin blocks its cleavage site with an N-terminal group, CJC-1295 in DAC form uses albumin binding like GLP-1 S, and Selank uses the same proline tail as Semax. Recognising which strategy a compound uses tells you what its certificate must account for.
The naming system itself settles it
There is a way to answer this question that does not depend on knowing any biology, and it is worth learning because it works on every other pair of drug names you will ever confuse.
Generic drug names are not invented freely. They are assigned by the World Health Organization under the International Nonproprietary Names programme, and they are built from stems: fixed word-endings that encode what class a substance belongs to. The stem is almost always at the end of the word, not the beginning. This is deliberate. The suffix carries the pharmacology; the prefix exists only to keep one member of the class distinguishable from another.
For peptides the stem is -tide. Narrow it further and you get -glutide, the stem the WHO assigns to analogues of glucagon-like peptide. Any substance whose name ends that way is being formally declared a member of that family, and the declaration is the whole point of the name. What sits in front of the stem is a distinguishing syllable chosen mainly for pronounceability and to avoid collisions with names already on the register.
Apply that to the pair in question. In the GLP-1 compound, the meaningful part of the name is the ending. The opening syllable is the arbitrary part, present only so the name differs from the others in its own class. Read correctly, the name announces a GLP-1 analogue and says nothing else.
Semax was not named under that system at all. It was coined by the Russian research group that developed it, from an entirely separate tradition, and its first syllable is the part that carries meaning rather than the part that was chosen to be forgettable. It has no WHO stem because it is not a registered international nonproprietary name.
So the three letters the two words share sit in the one position that the naming system reserves for information-free material, and the two names come from two systems that were never coordinated. The resemblance is not a hint of shared chemistry that has been obscured. Under the rules that produced the names, it is the specific kind of similarity that is guaranteed to mean nothing.
This is a general-purpose test. When two drug names look alike, compare the endings. Matching suffixes indicate a shared class and often genuinely similar behaviour. Matching beginnings, on their own, indicate a coincidence, because that is the position the system fills with material chosen precisely because it does not have to mean anything.
Verification: two different traps
Each compound fails in a way the other does not, and both traps are common.
GLP-1 S — the mass cannot come from the sequence
The finished molecule is backbone plus fatty acid plus linker, and those additions weigh something. So a mass-spectrometry result must be compared against the modified theoretical figure.
A certificate presenting a plain sequence and a mass computed from it was generated against a template for unmodified peptides. Nothing on it looks wrong — the number was simply calculated for a different substance.
There is a second issue at this length: synthesis yield compounds across every coupling step, so a 31-residue chain generates deletion sequences — chains short by one residue — which co-elute close to the target. The distribution of impurity across the chromatogram is more informative than the summed percentage.
Semax — the tail is shared
Semax and Selank both carry Pro-Gly-Pro, and several related constructs use the same design. On an HPLC trace they all present as one clean peak, so purity is weak identity evidence here. Their molecular weights differ; only mass spectrometry separates them.
And its methionine is partly visible on the trace — the sulfoxide elutes at a different retention time, so a notable secondary peak may be exactly that.
Field detail in how to read a certificate of analysis.
Handling
The divergence is air for one, time-in-solution for the other.
Semax: minimise draws. Every puncture of the stopper admits oxygen, and methionine oxidises readily. For a peptide without methionine that is a minor consideration; here it is the main one.
GLP-1 S: a long modified chain presents more hydrolysis- and oxidation-susceptible sites than a short peptide, so extended time in solution costs more. Reconstitute to consumption rather than to the vial. That concern concentrates in pen format, where the material has been dissolved since a fill date the label usually omits — the trade examined in pens versus vials.
Both share the rule most often broken: never re-freeze. Freeze-thaw damage is cumulative and completely invisible.
Procedure in reconstituting research peptides. Semax is also sold with Selank as a combined vial; the two are compared in Semax versus Selank.
Researchers in these areas commonly also hold GLP-2 T, GLP-3 R, Tesamorelin, Ipamorelin, NAD+, MOTS-c, DSIP and 5-Amino-1MQ. Supplier assessment is in choosing a research peptide supplier.
Frequently asked questions
Is Semax the same as semaglutide?
No. Semax is a seven-residue fragment of ACTH with a proline tail; semaglutide is a 31-residue GLP-1 analogue with a fatty-acid modification. They share four letters and nothing else.
Why do the names look similar?
Coincidence. 'Semaglutide' follows pharmaceutical naming for the GLP-1 analogue class; 'Semax' is a coined name from a Russian research programme and predates it.
Which is more fragile?
Semax has a specific liability — methionine at position one, which oxidises on air contact. GLP-1 S has no single weak point but its length means more sites vulnerable over time in solution.
Why can't GLP-1 S's mass be calculated from its sequence?
Because the fatty acid and linker add mass the sequence does not account for. A certificate reporting a plain sequence and a derived mass was generated from a template rather than measured.
Why is purity weak evidence for Semax?
Because it shares its Pro-Gly-Pro tail with Selank and similar constructs, all of which present as a clean single peak. Only mass spectrometry distinguishes them.
Do they share any mechanism?
No. They act on unrelated receptor systems and appear in unrelated research literatures. The only thing they share is the general problem their modifications solve — surviving clearance.
Related research compounds
Further reading
Research use only. All products referenced on this page are sold strictly for laboratory and research purposes. They are not drugs, foods, cosmetics, or medical devices, and they are not intended to diagnose, treat, cure, or prevent any disease. They are not for human or veterinary consumption. Handling should be performed only by qualified individuals in an appropriate laboratory setting.